MicroRNAs belong to the family of non-coding RNAs that participate in cell proliferation, cell death and development. The Müller glial cells are the inherent and specific neuroglia cells in the retinal organisation and play significant roles in retinal neuroprotection, organisational maintenance, inflammation and immunity, regeneration, and the occurrence and development of retinal diseases. However, only a few studies report the underlying mechanism of how miRNAs drive the function of Müller glial cells in the development of retinal diseases. This review aims to summarise the roles of miRNAs in retinal Müller glial cell function, including gliogenesis, inflammation and immunity, regeneration, the development of retinal diseases, and retinal development. This review may point out a novel miRNA-based insight into retinal repair and regeneration. MiRNAs in Müller glial cells may be considered a diagnostic and therapeutic target in the process of retinal repair and regeneration.
Dry eye disease (DED) is a prevalent ophthalmic disease that affects millions of people worldwide. Iron overload and macrophage inflammation have been implicated in the development of murine DED, though the specific role of macrophages under iron overload conditions remains unclear. This study aimed to establish a novel iron overload-induced mouse model of DED and investigate macrophage involvement. The model was induced via intraperitoneal injection of D-glucoside iron. Results showed that macrophage depletion via clodronate liposomes (CL) significantly mitigated iron deposit, decreased ocular surface inflammation, improved tear production and restored the structure of ocular surface tissues. Furthermore, CL specifically targeted pro-inflammatory M1 macrophages and reduced levels of the inflammatory cytokines IL-1β, IL-6, and TNF-α, effectively alleviating symptoms of DED. In conclusion, this study characterized a novel iron overload-induced DED mouse model and demenstrated that macrophage depletion mitigated the pathological changes in ocular surface and lacrimal gland tissues caused by iron overload, suggesting potential therapeutic strategies for further investigation in the treatment of DED.
Introduction: Exosomes are nanoscale extracellular vesicles that widely participate in intercellular communication. An increasing number of studies have reported on the neuroprotective effects of stem cell-derived exosomes in brain diseases through various delivery methods. However, only a few reports are available on the delivery and uptake of stem cell-derived exosomes in the brains of mice of different ages. Methods: PKH-26-labelled mesenchymal stem cell-derived exosomes were collected, and their uptake was investigated in the brains of mice aged 2 weeks, 2 months, and >6 months, 24 hours after intranasal delivery. Results: No exosomes were distributed in the whole brains of 2-week-old mice after 24 hours of intranasal delivery. However, a small number of exosomes were found in the olfactory bulb, cortex, and hippocampus of 2-month-old mice, with no exosomes observed in the cerebellum. In contrast, a large number of exosomes were ingested in all brain regions, including the olfactory bulb, cortex, hippocampus, and cerebellum, of >6-month-old mice. Conclusion: Exosomes can enter the brains of adult mice through intranasal administration, but there are differences in the uptake rate among mice of different ages. These findings provide a theoretical basis for the future clinical administration of exosomes for treating brain disorders.
Background: Inflammation significantly impacts the pathogenesis of age-related macular degeneration (AMD), the primary cause of vision loss in the elderly. With the aging global population and increasing incidence of AMD, understanding the inflammation-related mechanisms and identifying potential therapeutic targets have become paramount. This study aims to offer a bibliometric analysis of global research contributions focused on inflammation in AMD, shedding light on research trends, collaborations, and future directions. Methods: We retrieved publications related to inflammation in AMD from 2003 to 2023 from the Web of Science Core Collection database. A total of 2044 articles were analyzed using VOSviewer, CiteSpace, and R-bibliometrix to examine publication trends, influential countries, institutions, authors, and journals, as well as emerging research topics. Results: Our analysis revealed a steady global increase in annual publications. The United States and China emerged as leading contributors, demonstrating substantial collaboration and investment in AMD research. Among institutions, the National Eye Institute in the United States and the University of Eastern Finland stood out for their prolific contributions. Key researchers such as Kaarniranta have been central to advancing the field, offering potential collaboration opportunities. Investigative Ophthalmology and Visual Science and Experimental Eye Research were identified as the top journals publishing significant work on inflammation in AMD. Keywords such as “oxidative stress,” “complement” “autophagy,” “macrophage,” and “microglia” were frequently mentioned, highlighting these as current research hotspots. Conclusion: This analysis underscores the importance of inflammation in AMD and maps the evolution of research, suggesting future directions that may offer new therapeutic strategies.
Dry eye disease (DED) is a chronic ocular surface disorder triggered by tear film imbalance, in which inflammatory disruption of immune homeostasis constitutes the core pathological mechanism. Mesenchymal stem cell‐derived exosomes (MSC‐Exos) offer promising anti‐inflammatory therapeutic potential through immune modulation, tissue repair, and their inherently low immunogenicity. This review elucidates MSC‐Exos’ molecular regulation of DED inflammation, demonstrating their suppression of the TLR4/NF‐κB signaling axis, the IRAK1/TRAF6/NF‐κB cascade reaction, the STAT3 transcriptional regulatory network, and the NLRP3 inflammasome activation pathway, while revealing a synergistic mechanism through which MSC‐Exos ameliorate the ocular surface inflammatory microenvironment by modulating the Th17/Treg immune balance via the gut–eye axis and facilitating FBXW7‐mediated ubiquitination degradation pathways. Despite this therapeutic potential, clinical translation is hampered by exosomal heterogeneity, difficulties in standardization, and suboptimal delivery efficiency and long‐term efficacy. Future progress will require the integration of nanotechnology and gene editing to enhance therapeutic functionality, ultimately positioning MSC‐Exos as precision biologics for DED.